Table 3 The individual study-based data analysis to evaluate the effectiveness of these interventions on macular hole closure rate and VMT release rate

Benz et al. [37]

Ocriplasmin

Primavera et al. [53]

PV

Cacciamani et al. [61]

Ocriplasmin

Čokl et al. [54]

PV

Cacciamani et al. [62]

Ocriplasmin

Gruchociak et al. [63]

PV

Khanani et al. [64]

Ocriplasmin

Han et al. [41]

PV

Iuliano et al. [65]

Ocriplasmin

Arrigo et al. [66]

Ocriplasmin

Chatziralli et al. [67]

Ocriplasmin

Bormann et al. [68]

Ocriplasmin

Wertheimer et al. [69]

Ocriplasmin

Muqit et al. [46]

Ocriplasmin

Dugel et al. [40]

Ocriplasmin

Schumann et al. [49]

Ocriplasmin

Pirani et al. [70]

Ocriplasmin

Sharma et al. [50]

Ocriplasmin

Feng et al. [42]

Ocriplasmin

Steel et al. [57]

Ocriplasmin

Meyer et al. [71]

Ocriplasmin

Makris et al. [72]

Ocriplasmin

Mastropasqua et al. [73]

Ocriplasmin

Tadayoni et al. [74]

PPV

Muqit et al. [46]

Ocriplasmin

Zandi et al. [58]

Ocriplasmin

Nudleman et al. [47]

Ocriplasmin

Seamone et al. [75]

PV

Quezada-Ruiz et al. [48]

Ocriplasmin

Anderson et al. [21]

PV

Schumann et al. [49]

Ocriplasmin

Baumann et al. [59]

PV

Stalmans et al. [11]

Ocriplasmin

Fouad et al. [23]

PV

Makris et al. [72]

Ocriplasmin

Özdemir et al. [20]

PV

Warrow et al. [76]

Ocriplasmin

Willekens et al. [52]

Ocriplasmin

Itoh et al. [77]

Ocriplasmin

Kannan et al. [78]

PPV

Cereda et al. [79]

Ocriplasmin

Barca et al. [80]

Ocriplasmin

Paul et al. [81]

Ocriplasmin

Pessoa et al. [82]

Ocriplasmin

Wickens et al. [55]

PPV

Bormann et al. [68]

Ocriplasmin

Pessoa et al. [83]

Ocriplasmin

Nambiar et al. [27]

Ocriplasmin

Kim et al. [84]

Ocriplasmin

Scholz et al. [34]

Ocriplasmin

Schumann et al. [85]

Ocriplasmin

Sharma et al. [50]

Ocriplasmin

Steinle et al. [35]

Ocriplasmin

Tadayoni et al. [74]

PPV

Zandi et al. [58]

Ocriplasmin

Novack et al. [86]

Ocriplasmin

Sharma et al. [87]

Ocriplasmin

Figueira et al. [88]

Ocriplasmin

Tschuppert et al. [89]

Ocriplasmin

Reiss et al. [90]

Ocriplasmin

Singh et al. [91]

Ocriplasmin

Manousaridis et al. [92]

Ocriplasmin

Lim et al. [45]

Ocriplasmin

Chaudhary et al. [93]

PPV

Hejsek et al. [60]

PPV

Dihowm et al. [39]

PPV

Čokl et al. [54]

PV

Han et al. [41]

PV

Steel et al. [57]

Ocriplasmin

Baumann et al. [59]

PV

Özdemir et al. [20]

PV

Formula = \(\frac{{\mathrm{Number\, of\, Events}}}{{\mathrm{Total \,Number \,of\, eyes}}}\times 100\)

Total number of patients for MH treatment by ocriplasmin = \(\frac{1070}{2201}\times 100=48\cdot 6\%\)

Total number of patients for MH treatment by ocriplasmin = \(\frac{269}{580}\times 100=46\%\)

Total number of patients for MH treatment by PV = \(\frac{22}{46}\times 100=47\cdot 8\%\)

Total number of patients for MH treatment by PV = \(\frac{127}{187}\times 100=68\%\)

Total number of patients for MH treatment by PPV = \(\frac{485}{ 512}\times 100=95\%\)

Total number of patients for MH treatment by PPV = \(\frac{15}{15}\times 100=100\%\)